Search clinical trials for: AML, chidamide, decitabine

Total 485 results

Ruijin Hospital

Not yet recruiting

Efficacy of Pola-RCHP-X vs Pola-RCHP in Untreated DLBCL

Diffuse Large B-Cell Lymphoma
The First Affiliated Hospital of Soochow University

Recruiting

Study of A Venetoclax-based, Anthracycline-free Regimen in Newly Diagnosed CBFβ::MYH11(+) AML

Acute Myeloid Leukemia

China
M.D. Anderson Cancer Center
Ascentage Pharma Group Inc.

Not yet recruiting

A Phase I Study of Decitabine, Lisaftoclax, and Olverembatinib in Patients With Advanced Chronic Myeloid Leukemia and Philadelphia Chromosome-Positive Acute Myeloid Leukemia

Advanced Chronic Myeloid Leukemia | Philadelphia Chromosome-Positive Acute Myeloid Leukemia

United States
Chinese PLA General Hospital

Not yet recruiting

Chidamide+Decitabine Plus Anti-PD-1 Antibody in PD-1 Inhibitor Failed Patients With Classical Hodgkin Lymphoma.

PD-1 Inhibitor Failed Patients With Classical Hodgkin Lymphoma
The First Affiliated Hospital of Soochow University

Not yet recruiting

Decitabine, Venetoclax and Blinatumomab for Maintenance Following HSCT in Patients With Ph-Negative B-ALL

B-cell Acute Lymphoblastic Leukemia

China
M.D. Anderson Cancer Center

Not yet recruiting

Phase I/II Study of Engineered T Cell Receptor-Modified NK Cells Targeting PRAME in Conjunction With Lymphodepleting Chemotherapy for the Management of Relapse/Refractory Myeloid Malignancies

Myeloid Malignancies | Lymphodepleting Chemotherapy

United States
The First Affiliated Hospital of Soochow University

Recruiting

Maintenance Therapy of Hypomethylating Agent (HMA) in Favorable Risk Acute Myeloid Leukemia (AML) Patients

Acute Myeloid Leukemia

China
Case Comprehensive Cancer Center

Not yet recruiting

ASTX727 and Nivolumab in Squamous Cell Carcinoma of the Head and Neck

Head and Neck Squamous Cell Carcinoma | Recurrent Squamous Cell Carcinoma of the Head and Neck | Metastatic Squamous Cell Carcinoma

United States
Joseph Jurcic

Recruiting

DEC-C and Thioguanine for R/R AML

Acute Myeloid Leukemia

United States
Northside Hospital, Inc.

Not yet recruiting

Adding Venetoclax to the High-dose Chemotherapy Regimen Prior to Mismatche Allogeneic Stem Cell Transplant

Acute Myeloid Leukemia | Myelodysplastic Syndromes

United States
H. Lee Moffitt Cancer Center and Research Institute
Blueprint Medicines Corporation

Recruiting

Avapritinib With Decitabine in Patients With SM-AHN

Systemic Mastocytosis With an Associated Hematologic Neoplasm

United States
Children's Hospital of Soochow University

Recruiting

Safety and Efficacy of Avapritinib in Relapsed or Refractory Pediatric CBF-AML With KIT Mutation

AML, Childhood | C-KIT Mutation | Refractory AML | Relapse/Recurrence | Core Binding Factor Acute Myeloid Leukemia

China
M.D. Anderson Cancer Center
Astex Pharmaceuticals, Inc.

Not yet recruiting

A Phase I/II Trial to Assess the Efficacy and Toxicity of ASTX727 (Oral Decitabine/Cedazuridine) for the Treatment of Hematological Neoplasms After Allogeneic Stem Cell Transplantation

Allogeneic Stem Cell Transplantation

United States
Ruijin Hospital

Not yet recruiting

Compare the Efficacy and Safety of Dec-FB4 and FB4 as Conditioning Regimen for AML-MR

AML, Adult

China
Novo Nordisk A/S

Recruiting

A Study to Test How Either a Capsule or a Tablet With NDec (Decitabine and Tetrahydrouridine) Works in the Body of Healthy People

Healthy Volunteers

United States, Germany
The Second Affiliated Hospital of Kunming Medical...
Guizhou Provincial People's Hospital; Central South University; First Affiliated... and other collaborators

Not yet recruiting

Safety and Efficacy of Venetoclax Combination With Decitabine(DEC3-VEN) in the Treatment of AML in the Adult

Acute Myeloid Leukemia, Adult

China
M.D. Anderson Cancer Center

Not yet recruiting

Phase I/II Study of a Combination of Decitabine and Cedazuridine (ASTX727) and ASTX029, an ERK Inhibitor, for Patients With RAS Pathway Mutant Myelodysplastic Syndromes and Myelodysplastic/Myeloproliferative Neoplasms

Myeloproliferative Neoplasm | Myelodysplastic Neoplasm | Pathway Mutant Myelodysplastic Syndromes

United States
Pamela Munster
National Cancer Institute (NCI)

Recruiting

Olaparib and ASTX727 in BRCA1/2- and Homologous Recombination Deficient (HRD)-Mutated Tumors

BRCA1 Mutation | BRCA2 Mutation | PALB2 Gene Mutation | ATM Gene Mutation | BRCA Mutation | Checkpoint Kinase 2 Gene Mutation

United States
University Hospital Tuebingen

Recruiting

Combination Salvage Therapy With Venetoclax and Decitabine in Relapsed/Refractory AML (VenSwitch)

AML | MDS

Germany
Benjamin Tomlinson

Not yet recruiting

Decitabine and Venetoclax Treatment as Maintenance Therapy in Patients Post Allograft Stem Cell Transplant

Acute Myeloid Leukemia | Myeloid Malignancy

United States
Otsuka Beijing Research Institute

Recruiting

PK/Efficacy Bridging Study of ASTX727 in Chinese Subjects With Myelodysplastic Syndromes

Myelodysplastic Syndromes

China
The Second Affiliated Hospital of Kunming Medical...

Not yet recruiting

Comparison of the Efficacy and Safety of Venetoclax in Combination With 3 Days Decitabine (DEC3-VEN) vs. Venetoclax in Combination With Azacitidine (VIALE-A) in the Treatment of Elderly Patients or Unfit, New-diagnosis Acute Myeloid Leukemia Patients

Acute Myeloid Leukemia | Decitabine | Venetoclax | Elderly AML Patients | Unfit, New-diagnosis AML

China
First Affiliated Hospital of Zhejiang University

Recruiting

Prolonged Ultra Low-dose Decitabine Plus Venetoclax for Primary Diagnosed Elderly AMLK/MDS

Acute Myeloid Leukemia | Myelodysplastic Syndromes

China
Loyola University
Karyopharm Therapeutics Inc

Recruiting

Decitabine and Selinexor in Combination to Reverse Drug Resistance With Standard Chemotherapy in Ovarian Cancer

Ovarian Cancer

United States
National Cancer Institute (NCI)

Recruiting

Decitabine/Cedazuridine (INQOVI), an Oral DNA Demethylating Agent, in Subjects With BAP1 Cancer Predisposition Syndrome and Subclinical, Early-Stage Mesothelioma

Mesothelioma | BRCA1-Associated Protein-1 (BAP1) Mutations | Malignant Mesothelioma (MM) | Early-stage Mesothelioma | Subclinical Mesothelioma | Early-stage BAP1-associated Malignancies

United States
National Cancer Institute (NCI)

Recruiting

Eltanexor (KPT-8602) With Inqovi (Decitabine-Cedazuridine) in High-Risk Myelodysplastic Syndromes

Myelodysplastic Syndromes

United States
The First Affiliated Hospital of Soochow University

Not yet recruiting

Decitabine for Poor Graft Function Post Allo-HSCT

Poor Graft Function
Otsuka Australia Pharmaceutical Pty Ltd

Recruiting

A Study Comparing Treatment Preference Between Oral Decitabine/Cedazuridine and Azacitidine in Myelodysplastic Syndrome, Low-Blast Acute Myeloid Leukemia, or Chronic Myelomonocytic Leukemia (PREFER-HMA)

Myelodysplastic Syndromes | Leukemia, Myeloid, Acute | Leukemia, Myelomonocytic, Chronic | Patient Preference

New Zealand, Australia
Shanghai General Hospital, Shanghai Jiao Tong University...

Recruiting

Hypomethylating Agent and Venetoclax After Allo-HSCT in Patients With High-risk Myeloid Malignancies.

Myeloid Malignancy | Venetoclax | Hypomethylating Agent

China
PureTech

Recruiting

A Phase 1 Study With LYT-200 in Patients With Relapsed/Refractory Acute Myeloid Leukemia (AML), or With Relapsed/Refractory, High-risk Myelodysplastic Syndrome (MDS)

MDS | AML, Adult Recurrent

United States
EpiDestiny, Inc.
Worldwide Clinical Trials

Recruiting

To Study the Oral Bioavailability of a New Combination Formation of Decitabine and Tetrahydrouridine in Healthy Males

Healthy

United States
Chinese PLA General Hospital

Recruiting

Decitabine and Anti-PD-1 in R/R DLBCL

Diffuse Large B Cell Lymphoma | Central Nervous System Lymphoma | Extranodal Extension | Relapse/Recurrence

China
The First Affiliated Hospital of Soochow University

Not yet recruiting

Selinexor and HAAG With/Without HMA in Relapsed/Refractory Acute Leukemia (AML) Patients

Relapsed/Refractory AML

China
Sanjay Mohan
National Comprehensive Cancer Network; Taiho Oncology, Inc.

Recruiting

Decitabine and Cedazuridine in Combination With Venetoclax for the Treatment of Patients Who Have Relapsed Acute Myeloid Leukemia After Donor Stem Cell Transplant

Recurrent Acute Myeloid Leukemia

United States
Franziska Wachter
Harvard Clinical and Translational Science Center (Harvard Catalyst)

Recruiting

A Pilot Study to Evaluate the Feasibility of Post-Hematopoietic Stem Cell Transplant Prophylaxis With Decitabine Combined With Filgrastim for Children and Young Adults With AML, MDS and Related Myeloid Malignancies (MORE)

Acute Myeloid Leukemia | Myelodysplastic Syndromes | MDS | Aml | Myeloid Neoplasm | Myeloid Malignancies | Inherited Bone Marrow Failure Syndrome

United States
University of Florida

Not yet recruiting

Trial of Cladribine and Low-Dose Cytarabine (LoDAC) Alternating With Decitabine vs. Hypomethylating Agents (HMA) Plus Venetoclax as Frontline Therapy for AML or High-Grade MDS in Patients Unfit for Intensive Induction

Acute Myeloid Leukemia | Myelodysplastic Syndromes
Princess Maxima Center for Pediatric Oncology
Innovative Therapies For Children with Cancer Consortium; IBFM; Fight Kids Cancer

Not yet recruiting

HEM-iSMART-A: Decitabine / Venetoclax and Navitoclax in Pediatric Patients With Relapsed or Refractory Hematological Malignancies (HEM-iSMART A)

Acute Lymphoblastic Leukemia, in Relapse | Lymphoblastic Lymphoma (Precursor B-Lymphoblastic Lymphoma/Leukaemia) Recurrent | Lymphoblastic Lymphoma (Precursor T-Lymphoblastic Lymphoma/Leukaemia) Recurrent | Lymphoblastic Lymphoma (Precursor B-Lymphoblastic Lymphoma/Leukaemia) Refractory | Lymphoblastic Lymphoma (Precursor T-Lymphoblastic Lymphoma/Leukaemia) Refractory

Netherlands
The First Affiliated Hospital of Soochow University

Not yet recruiting

Decitabine and Umbilical Cord Blood for Poor Graft Function Post Allo-HSCT

Poor Graft Function
Fudan University

Not yet recruiting

Low Dose Decitabine in Combination With Tirelizumab Comparison of Tirelizumab in the First-line Treatment of Advanced Esophageal Squamous Cell Carcinoma

PFS
Clinical Hub for Interventional Research (CHOIR)
The University of New South Wales; Australian National University

Recruiting

Combined Evaluation of Epigenetic and Sensitising Therapy in AML and MDS (CELESTIAL-MDS)

Acute Myeloid Leukemia | Myelodysplastic Syndromes | Chronic Myelomonocytic Leukemia

Australia
National Cancer Institute (NCI)

Recruiting

Venetoclax in Combination With ASTX727 for the Treatment of Chronic Myelomonocytic Leukemia and Other Myelodysplastic Syndrome/Myeloproliferative Neoplasm

Chronic Myelomonocytic Leukemia | Myelodysplastic Syndrome | Myelodysplastic Syndrome With Excess Blasts | Myeloproliferative Neoplasm

United States, Canada
Sunshine Lake Pharma Co., Ltd.

Recruiting

HEC73543 Versus Salvage Chemotherapy in R/R FLT3-ITD AML

Leukemia, Acute Myeloid (AML)

China
Thomas Jefferson University
AbbVie

Recruiting

Evaluating Navitoclax After Failure of Standard Treatments of Azacitidine or Decitabine and Venetoclax in Patients With Aggressive Myelodysplastic Syndrome

Myelodysplastic Syndrome | Recurrent Myelodysplastic Syndrome | Refractory Myelodysplastic Syndrome

United States
Zhejiang University

Recruiting

Venetoclax and Decitabin Based Conditioning Regimen Followed With Post-HSCT Decitabin Maintenance Therapy in TP53 Mutant AML/MDS Patients

Hematopoietic Stem Cell Transplantation | TP53

China
Sun Yat-sen University
Hutchmed

Recruiting

Pamiparib Plus Surufatinib in Patients With Platinum-resistant Ovarian Cancer

Ovarian Cancer | Platinum-resistant Ovarian Cancer | Primary Peritoneal Cancer | Ovarian Carcinoma | Fallopian Tube Carcinosarcoma

China
Jacqueline Garcia, MD
AbbVie

Recruiting

Combination Navitoclax, Venetoclax and Decitabine for Advanced Myeloid Neoplasms

Acute Myeloid Leukemia | Myelodysplastic Syndromes | Myelofibrosis | Myeloid Malignancy | Myeloproliferative Neoplasm

United States
Nanfang Hospital of Southern Medical University
Peking University People's Hospital; Guangzhou First People's Hospital; Sun Yat-Sen... and other collaborators

Recruiting

G-CSF+DAC+BUCY vs G-CSF+DAC+BF Conditioning Regimen for High-risk MDS Undergoing Allo-HSCT

Myelodysplastic Syndrome | Allogeneic Hematopoietic Stem Cell Transplantation | Conditioning

China
Nanfang Hospital of Southern Medical University
Peking University People's Hospital; Guangzhou First People's Hospital; Sun Yat-Sen... and other collaborators

Recruiting

G-CSF+DAC+BUCY vs G-CSF+DAC+BF Conditioning Regimen for Secondary Acute Myeloid Leukemia Undergoing Allo-HSCT

Allogeneic Hematopoietic Stem Cell Transplantation | Conditioning | Secondary Acute Myeloid Leukemia Evolving From MDS

China
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Recruiting

Clinical Study of TQB2618 Injection in Combination With Demethylation Drugs in Patients With Recurrent/Refractory Acute Myeloid Leukemia, Myelodysplastic Syndromes

Recurrent/Refractory Acute Myeloid Leukemia, Myelodysplastic Syndromes

China
Novo Nordisk A/S

Recruiting

Research Study Investigating How Well NDec Works in People With Sickle Cell Disease (ASCENT1)

Sickle Cell Disease

Spain, United States, United Kingdom, Canada, Italy, India, Turkey, Greece, South Africa, France, Lebanon, Oman

Search clinical trials for: AML, chidamide, decitabine

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Lithuania

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations